PRINCETON, N.J., June 7 /PRNewswire-FirstCall/ -- Cytogen Corporation (Nasdaq: CYTO - News) today announced the presentation of data from a series of investigator-sponsored studies of QUADRAMET® (samarium Sm-153 lexidronam injection) in a variety of therapeutic combinations and applications. Results were presented at the 53rd Society of Nuclear Medicine (SNM) annual meeting taking place this week in San Diego, California.
